U.S. Chemicals Stock News

NasdaqGM:DAVE
NasdaqGM:DAVEConsumer Finance

Assessing Dave (DAVE) Valuation As It Joins The S&P SmallCap 600 Index

Dave (DAVE) is set to join the S&P SmallCap 600 Index before trading opens on June 1, 2026, a milestone that often draws fresh attention from index-linked and benchmark-aware investors. See our latest analysis for Dave. Dave’s recent inclusion in the S&P SmallCap 600 and its appearance at the Barrington Research conference come after a sharp near term share price move, with a 7 day share price return of 23.68% and a 1 year total shareholder return of 40.70%. This points to momentum that has...
NYSE:SE
NYSE:SEMultiline Retail

Should Shopee’s Surprise Q1 Outperformance and Cash Strength Require Action From Sea (SE) Investors?

In the past quarter, Sea Limited reported strong results across e-commerce, digital financial services, and gaming, generated about US$4.50 billion in free cash flow last year, and continued its US$1.00 billion share repurchase program. A key insight is that Shopee’s gross merchandise value growth outpaced both internal guidance and external expectations, prompting several analysts to reassess Sea’s longer-term earnings potential and business quality. We’ll now examine how Sea’s...
NYSE:REX
NYSE:REXOil and Gas

The Bull Case For REX American Resources (REX) Could Change Following Record Q1 EPS And Tax Credits

REX American Resources reported past first-quarter 2026 results with sales of US$156.5 million, net income of US$18.45 million, and basic earnings per share of US$0.56 from continuing operations, compared with the prior year’s US$158.34 million in sales, US$8.68 million in net income, and US$0.26 in earnings per share. The quarter marked the most profitable first quarter in the company’s history on a per-share basis, underpinned by Section 45Z production tax credits, lower corn costs, and...
NasdaqGS:INTU
NasdaqGS:INTUSoftware

Assessing Intuit (INTU) Valuation After Workforce Cuts And Raised 2026 Guidance

Intuit (INTU) has been in focus after announcing a 17% workforce reduction, alongside higher fiscal 2026 revenue and earnings guidance. This combination landed just as TurboTax usage and revenue expectations softened. See our latest analysis for Intuit. Despite a 1-day share price return of 5.92% taking Intuit to US$331.53, the stock is still down 16.92% on a 30-day share price basis and the 1-year total shareholder return has declined 55.64%. This points to weak momentum even after the...
NYSE:AIT
NYSE:AITTrade Distributors

Is It Too Late To Consider Applied Industrial Technologies (AIT) After Its Strong Multi Year Rally?

Wondering if Applied Industrial Technologies at around US$303 per share still offers value, or if most of the opportunity is already reflected in the price. The stock is roughly flat over the past month, edging up 0.3%, yet it is up 17.0% year to date and 35.1% over the past year, with a 3 year return of 134.1% and a 5 year return of 229.2%. These figures can change how the market views its risk and reward profile. Recent coverage of Applied Industrial Technologies has focused on its role in...
NasdaqGS:AEVA
NasdaqGS:AEVAElectronic

Aeva Technologies (AEVA) Is Up 11.3% After LiDAR Demand Shifts Toward Robotics And Physical AI

Recent commentary on Aeva Technologies highlights a shift in the LiDAR market from an exclusive focus on autonomous vehicles to broader deployment across robotics, drones and physical AI systems, supported by advances in solid-state and FMCW LiDAR that are lowering costs and improving performance. An important new insight is that robotics-related LiDAR shipments now exceed automotive advanced driver assistance volumes, pointing to faster adoption in non-automotive markets and subtly...
NYSE:GENI
NYSE:GENIHospitality

Is Genius Sports' (GENI) Moment Engine Turning Ad Timing Into a Lasting Competitive Edge?

In May 2026, Genius Sports released biometric research with MediaScience showing that ads aired right after emotionally intense live sports moments can roughly double unaided brand recall, highlighting the importance of timing in sports advertising. The study underpins Genius Sports’ Moment Engine, which uses real-time official game data to trigger ads in the peak 60-second attention window after high-impact plays, suggesting that optimizing when ads appear may matter more than changing the...
NYSE:NOC
NYSE:NOCAerospace & Defense

Is Northrop Grumman (NOC) Pricing In Too Much Future Growth After Recent Share Gains?

Wondering if Northrop Grumman at around US$563.68 is offering fair value, or if the current price is out of line with what you get for owning the stock? The stock is up 1.5% over the past week, slightly down 0.8% over the last 30 days, and shows returns of 18.1% over 1 year, 32.9% over 3 years, and 61.2% over 5 years. This raises questions about how much of this is already reflected in the current price. Recent coverage has focused on Northrop Grumman's role as a large US defense contractor...
NYSE:NMAX
NYSE:NMAXMedia

Assessing Newsmax (NMAX) Valuation After Recent Volatile Share Price Performance

Setting the scene for Newsmax stock Newsmax (NMAX) has drawn fresh attention after recent trading left the stock at US$8.51, with performance metrics over the past month and past 3 months giving investors more data to assess its media-focused business. See our latest analysis for Newsmax. Recent trading has been volatile, with a 30 day share price return of 33.39% and a 90 day share price return of 31.53%. However, the 1 year total shareholder return has declined 53.52%, suggesting recent...
NYSE:ENS
NYSE:ENSElectrical

EnerSys Resets Segments To Clarify Growth Drivers And Margins

EnerSys (NYSE:ENS) plans to reorganize its operations into three focused business units starting in its 2027 fiscal year. The company is shifting from its current four segment structure to a new model aimed at a clearer focus on key markets and customer needs. The realignment is intended to streamline operations and guide how EnerSys allocates resources across its core businesses. EnerSys operates in stored energy solutions, supplying products and systems used across industrial,...
NasdaqCM:SLS
NasdaqCM:SLSBiotechs

Assessing SELLAS Life Sciences Group (SLS) Valuation After A Sharp Multi‑Month Share Price Surge

Why SELLAS Life Sciences Group (SLS) Is On Investors’ Radar SELLAS Life Sciences Group (SLS) has drawn attention after a strong recent share price move, with the stock posting large gains over the past month and past 3 months. That price action is prompting investors to look more closely at what is driving sentiment around this late stage, oncology-focused company. See our latest analysis for SELLAS Life Sciences Group. The recent surge is part of a broader move, with a 30 day share price...
NYSE:TAP
NYSE:TAPBeverage

A Look At Molson Coors (TAP) Valuation After Senior Notes Sale And New Summer Marketing Push

Molson Coors Beverage (TAP) is back in focus after launching a US$1.5b underwritten senior notes offering, while also rolling out summer themed Lager Luggage products and a limited edition Coors Banquet x Wrangler apparel collaboration. See our latest analysis for Molson Coors Beverage. Despite the fresh marketing pushes and new bond offerings, Molson Coors Beverage’s 1 day share price return fell 2.56% to US$39.53, while its 1 year total shareholder return declined 22.37%. This points to...
NYSE:HLI
NYSE:HLICapital Markets

Houlihan Lokey (HLI) Valuation Check After Recent Share Price Weakness

Houlihan Lokey stock: recent performance snapshot Houlihan Lokey (HLI) has drawn fresh attention after a period of weaker share performance. The stock is down roughly 20% year to date and about 18% over the past year. See our latest analysis for Houlihan Lokey. The recent pullback has not been limited to a single session, with the stock falling 2.82% on the day, 6.58% over the past week and 7.46% over the past month. The 1 year total shareholder return is down 17.80%, while the 5 year total...
NasdaqCM:VRRM
NasdaqCM:VRRMProfessional Services

Verra Mobility (VRRM) Loses Avis Contract: How Exposed Is Its Customer Concentration Strategy?

Earlier this week, Verra Mobility was hit by the loss of its contract with Avis, prompting several major Wall Street firms to reassess the company’s outlook and ratings. The termination of a key rental car partnership highlights Verra Mobility’s exposure to customer concentration risk and the importance of contract stability in its business model. We’ll now examine how the loss of the Avis contract and related concentration concerns may reshape Verra Mobility’s investment narrative. The...
NasdaqGS:ICLR
NasdaqGS:ICLRLife Sciences

Is It Time To Revisit ICON (ICLR) After Recent Share Price Rebound

Wondering whether ICON at US$136.07 is starting to look like value again, or if the stock still carries a premium. The share price has moved sharply in the short term, with a 16.5% gain over the last 7 days and 20.6% over the last 30 days, yet year to date the stock is still down 27.9% and the 3 year and 5 year returns are down 38.6% and 38.3% respectively, compared with a 4.4% gain over the last year. Recent news flow around ICON has focused on broader sector sentiment and how contract...
NasdaqGS:FISV
NasdaqGS:FISVDiversified Financial

Assessing Fiserv (FISV) Valuation As AI Partnership With Cognition Signals A Deeper Technology Overhaul

Fiserv (FISV) has put AI at the center of its technology plans, partnering with Cognition to deploy Devin, an AI software engineer, to modernize core banking systems and shorten release cycles for financial institution clients. See our latest analysis for Fiserv. Fiserv’s recent AI partnerships and product launches come as the stock trades at US$56.56, with the share price down around 9% over the past month and year to date, and total shareholder returns falling sharply over one and five...
NYSE:MRK
NYSE:MRKPharmaceuticals

Assessing Merck (MRK) Valuation After Mixed Short Term Performance And Conflicting Fair Value Signals

Merck stock triggered by recent performance metrics Merck (MRK) is back on investors’ radar after a recent stretch of mixed share performance, including a gain of about 6% over the past month alongside modest declines over the past week. See our latest analysis for Merck. Short term momentum has softened, with the share price down 3.0% over the past week after a 5.9% gain over 30 days. However, the year to date share price return of 11.5% and 1 year total shareholder return of 60.1% point to...
NYSE:MX
NYSE:MXSemiconductor

Magnachip Semiconductor (MX) Valuation Check As AI Power MOSFET Showcase Draws New Attention

Magnachip Semiconductor (MX) has drawn fresh investor attention after announcing plans to showcase its Medium Voltage MOSFET portfolio for AI server and data center power systems at PCIM Europe 2026 in Nuremberg. See our latest analysis for Magnachip Semiconductor. The latest AI server and data center announcement lands after a strong run in the stock, with a 90 day share price return of 220% and a 1 year total shareholder return of 143.77%, although the 5 year total shareholder return shows...
NasdaqCM:NESR
NasdaqCM:NESREnergy Services

National Energy Services Reunited Shelf Filing And Future Dilution Tradeoffs

National Energy Services Reunited (NasdaqCM:NESR) has filed a shelf registration to potentially issue a significant amount of new ordinary shares. The filing allows NESR to offer equity securities over time, rather than in a single transaction. The move signals that the company is preparing for possible capital-raising activities, subject to market conditions and internal needs. National Energy Services Reunited operates in the oilfield services space, supporting energy producers across...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Why Guardant Health (GH) Is Up 9.0% After ACS Adds Shield Test to Screening Guidelines

In May 2026, Guardant Health announced that its FDA-approved Shield blood test was added to updated American Cancer Society colorectal cancer screening guidelines as a blood-based option for average-risk adults 45 and older who decline or do not complete traditional tests. This guideline inclusion, alongside recent FDA clearance of the expanded Guardant360 Liquid CDx panel, highlights growing clinical recognition of Guardant’s blood-based cancer diagnostics across both screening and...
NasdaqGS:ARM
NasdaqGS:ARMSemiconductor

Why Arm Holdings (ARM) Is Up 15.3% After AI CPU Push And Manufacturing Move - And What's Next

In recent days, Arm Holdings has reported strong momentum in AI-related licensing and royalties while announcing a move into manufacturing its own CPUs, just as easing geopolitical tensions and improving macro signals lifted demand expectations for AI infrastructure across global markets. This combination of expanding AI partnerships, a broader role in the CPU value chain, and a more supportive risk backdrop is sharpening investor focus on how AI workloads and custom silicon could reshape...
NasdaqGS:OCFC
NasdaqGS:OCFCBanks

A Look At OceanFirst Financial (OCFC) Valuation As Shares Trade Below Popular Fair Value Estimate

Recent performance snapshot OceanFirst Financial (OCFC) has drawn attention after recent price moves, with the stock now around $18.79. Short term performance has been mixed, including a small daily decline and a modest gain over the past week. See our latest analysis for OceanFirst Financial. Viewed over a longer stretch, OceanFirst Financial’s 5.3% year to date share price return and 16.9% one year total shareholder return suggest steady rather than explosive momentum as investors reassess...
NYSE:CCL
NYSE:CCLHospitality

Carnival (CCL) Valuation Check After Recent Share Price Rebound And Recovery Narrative

Carnival (CCL) is back in focus after recent trading, with the stock closing at $28.06 and short-term returns showing mixed momentum over the past week, month, and past 3 months. See our latest analysis for Carnival. Recent trading has pushed Carnival’s 7 day share price return to 8.01%, yet the stock is still down 9.25% year to date, while the 1 year total shareholder return is 22.15%. This suggests recent momentum follows a longer recovery trend rather than a fresh breakout. If this kind of...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

A Look At Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery

Iovance Biotherapeutics (IOVA) has drawn fresh attention after recent share price moves, prompting investors to reassess how its cell therapy pipeline, commercial products, and financial profile fit into their portfolios. See our latest analysis for Iovance Biotherapeutics. Recent trading reflects a mixed picture, with a 20.59% 1 month share price return and a 62.70% year to date share price return. However, the 5 year total shareholder return shows a decline of 77.12%, suggesting momentum...